Literature DB >> 32494194

Gene Expression Signature to Predict Prognosis and Adjuvant Chemosensitivity of Colorectal Cancer Patients.

Jianxia Li1, Jianwei Zhang1, Huabin Hu1, Yue Cai1, Jiayu Ling1, Zehua Wu1, Yanhong Deng1.   

Abstract

PURPOSE: Molecular characteristics using gene-expression profiling can undoubtedly improve the prediction of treatment responses, and ultimately, the clinical outcome of cancer patients. We aimed at developing a genetic signature to improve the prediction of chemosensitivity and prognosis of patients with colorectal cancer (CRC). PATIENTS AND METHODS: We analyzed microarray data of 32 CRC patients to explore the potential functions and pathways involved in the disease relapse in CRC. Gene expression profiles and clinical follow-up information of GSE39582, GSE17536, and GSE103479 were downloaded from the Gene Expression Omnibus database (GEO) to identify prognostic genes. Eventually, a model of 15-mRNA signature was established, in which its efficacy for predicting chemosensitivity and prognosis was examined.
RESULTS: Based on the proposed model of 15-mRNA signature, the test series patients could be classified into high-risk or low-risk subgroup with significantly different overall survival (OS) rate (hazard ratio [HR]=1.48, 95% confidence interval [CI]=1.30-1.70, P≤0.001). The prognostic value of this 15-mRNA signature was confirmed in another validation series. Further analysis revealed that the prognostic value of this signature was independent of the TNM stage and can predict adjuvant chemosensitivity of patients with early-stage CRC.
CONCLUSION: We identified a novel 15-mRNA signature in patients with CRC, which could be clinically helpful in the prognosis evaluation and the process of selection of patients with early-stage CRC for undergoing adjuvant chemotherapy.
© 2020 Li et al.

Entities:  

Keywords:  a 15-gene signature; chemosensitivity; colorectal cancer (CRC); prognosis; risk score; survival

Year:  2020        PMID: 32494194      PMCID: PMC7227814          DOI: 10.2147/CMAR.S243490

Source DB:  PubMed          Journal:  Cancer Manag Res        ISSN: 1179-1322            Impact factor:   3.989


  45 in total

Review 1.  The expression and role of CXC chemokines in colorectal cancer.

Authors:  Hannelien Verbeke; Sofie Struyf; Geneviève Laureys; Jo Van Damme
Journal:  Cytokine Growth Factor Rev       Date:  2011-10-14       Impact factor: 7.638

2.  Cancer statistics, 2019.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2019-01-08       Impact factor: 508.702

3.  Functional polymorphisms of ITGB1 are associated with clinical outcome of Chinese patients with resected colorectal cancer.

Authors:  Feng Zhou; Xiaojun Huang; Zhaohui Zhang; Yibing Chen; Xiaonan Liu; Jinliang Xing; Xianli He
Journal:  Cancer Chemother Pharmacol       Date:  2015-04-17       Impact factor: 3.333

4.  Lymph nodes, tumor deposits, and TNM: are we getting better?

Authors:  Iris D Nagtegaal; Tibor Tot; David G Jayne; Phil McShane; Anders Nihlberg; Helen C Marshall; Lars Påhlman; Julia M Brown; Pierre J Guillou; Philip Quirke
Journal:  J Clin Oncol       Date:  2011-05-09       Impact factor: 44.544

5.  limma powers differential expression analyses for RNA-sequencing and microarray studies.

Authors:  Matthew E Ritchie; Belinda Phipson; Di Wu; Yifang Hu; Charity W Law; Wei Shi; Gordon K Smyth
Journal:  Nucleic Acids Res       Date:  2015-01-20       Impact factor: 16.971

6.  Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis.

Authors:  Inti Zlobec; Michel P Bihl; Heike Schwarb; Luigi Terracciano; Alessandro Lugli
Journal:  Int J Cancer       Date:  2010-07-15       Impact factor: 7.396

7.  The BRAF mutation is associated with the prognosis in colorectal cancer.

Authors:  Tae Sung Ahn; Dongjun Jeong; Myoung Won Son; Haeil Jung; Soyoung Park; Hyungjoo Kim; Sang Byung Bae; Han Jo Kim; Young-Woo Jeon; Moon Soo Lee; Moo-Jun Baek
Journal:  J Cancer Res Clin Oncol       Date:  2014-06-19       Impact factor: 4.553

8.  Glutamatergic synaptic input to glioma cells drives brain tumour progression.

Authors:  Varun Venkataramani; Dimitar Ivanov Tanev; Christopher Strahle; Alexander Studier-Fischer; Laura Fankhauser; Tobias Kessler; Christoph Körber; Markus Kardorff; Miriam Ratliff; Ruifan Xie; Heinz Horstmann; Mirko Messer; Sang Peter Paik; Johannes Knabbe; Felix Sahm; Felix T Kurz; Azer Aylin Acikgöz; Frank Herrmannsdörfer; Amit Agarwal; Dwight E Bergles; Anthony Chalmers; Hrvoje Miletic; Sevin Turcan; Christian Mawrin; Daniel Hänggi; Hai-Kun Liu; Wolfgang Wick; Frank Winkler; Thomas Kuner
Journal:  Nature       Date:  2019-09-18       Impact factor: 49.962

9.  Integrative Genome-Scale DNA Methylation Analysis of a Large and Unselected Cohort Reveals 5 Distinct Subtypes of Colorectal Adenocarcinomas.

Authors:  Lochlan Fennell; Troy Dumenil; Leesa Wockner; Gunter Hartel; Katia Nones; Catherine Bond; Jennifer Borowsky; Cheng Liu; Diane McKeone; Lisa Bowdler; Grant Montgomery; Kerenaftali Klein; Isabell Hoffmann; Ann-Marie Patch; Stephen Kazakoff; John Pearson; Nicola Waddell; Pratyaksha Wirapati; Paul Lochhead; Yu Imamura; Shuji Ogino; Renfu Shao; Sabine Tejpar; Barbara Leggett; Vicki Whitehall
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2019-04-05

10.  The consensus molecular subtypes of colorectal cancer.

Authors:  Justin Guinney; Rodrigo Dienstmann; Xin Wang; Aurélien de Reyniès; Andreas Schlicker; Charlotte Soneson; Laetitia Marisa; Paul Roepman; Gift Nyamundanda; Paolo Angelino; Brian M Bot; Jeffrey S Morris; Iris M Simon; Sarah Gerster; Evelyn Fessler; Felipe De Sousa E Melo; Edoardo Missiaglia; Hena Ramay; David Barras; Krisztian Homicsko; Dipen Maru; Ganiraju C Manyam; Bradley Broom; Valerie Boige; Beatriz Perez-Villamil; Ted Laderas; Ramon Salazar; Joe W Gray; Douglas Hanahan; Josep Tabernero; Rene Bernards; Stephen H Friend; Pierre Laurent-Puig; Jan Paul Medema; Anguraj Sadanandam; Lodewyk Wessels; Mauro Delorenzi; Scott Kopetz; Louis Vermeulen; Sabine Tejpar
Journal:  Nat Med       Date:  2015-10-12       Impact factor: 53.440

View more
  4 in total

1.  Clinical Significance and Inflammatory Landscape of aNovel Recurrence-Associated Immune Signature in Stage II/III Colorectal Cancer.

Authors:  Zaoqu Liu; Taoyuan Lu; Jing Li; Libo Wang; Kaihao Xu; Qin Dang; Long Liu; Chunguang Guo; Dechao Jiao; Zhenqiang Sun; Xinwei Han
Journal:  Front Immunol       Date:  2021-07-29       Impact factor: 7.561

2.  Identification of an Immune-Related Gene Signature to Improve Prognosis Prediction in Colorectal Cancer Patients.

Authors:  Siqi Dai; Shuang Xu; Yao Ye; Kefeng Ding
Journal:  Front Genet       Date:  2020-12-04       Impact factor: 4.599

3.  Gene Expression Profile Reveals a Prognostic Signature of Non-MSI-H/pMMR Colorectal Cancer.

Authors:  Zaoqu Liu; Hui Xu; Xiaoyong Ge; Siyuan Weng; Qin Dang; Xinwei Han
Journal:  Front Cell Dev Biol       Date:  2022-02-17

4.  Development and clinical validation of a novel six-gene signature for accurately predicting the recurrence risk of patients with stage II/III colorectal cancer.

Authors:  Zaoqu Liu; Taoyuan Lu; Jing Li; Libo Wang; Kaihao Xu; Qin Dang; Chunguang Guo; Long Liu; Dechao Jiao; Zhenqiang Sun; Xinwei Han
Journal:  Cancer Cell Int       Date:  2021-07-07       Impact factor: 5.722

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.